UroGen Pharma Ltd. (URGN) Earnings Call Transcripts
UroGen Pharma Ltd.'s Latest Earnings Call - June 10, 2026
In Q1 2026, UroGen Pharma Ltd. reported strong performance driven by the successful launch of ZUSDURI, which has outpaced JELMYTO in terms of adoption. Revenue figures were not disclosed, but management emphasized the ease of use and compelling clinical data of ZUSDURI as key factors in its early success. The company is focusing on expanding its uro-oncology portfolio and anticipates filing for UGN-103 by Q3 2026, with an expected approval in 2027. Guidance for 2026 was not explicitly updated, but the company is optimistic about continued growth and market penetration.
Reported metrics
| Metric | Value |
|---|---|
| ZUSDURI Complete Response Rate | 80% at 12 months (positive) |
| Physician Adoption Rate | 92% of docs plan to use ZUSDURI (positive) |
| UGN-103 Filing Timeline | Q3 2026 (neutral) |
| UGN-501 Phase I Trial | Initiation in 2026 (neutral) |
Guidance from management
Management expects to file for UGN-103 by Q3 2026, with approval anticipated in 2027. They plan to maintain both ZUSDURI and UGN-103 on the market until reimbursement mechanisms are fully in place for the latter.
What analysts pressed on
Analysts are focused on the sustainability of ZUSDURI's adoption rate and the ability to manage supply and reimbursement challenges effectively. Questions also arose about the long-term strategy for UGN-103 and its market differentiation.
Main topics on the call
- ZUSDURI Launch Success — ZUSDURI has seen rapid adoption due to its ease of administration and strong clinical data, including an 80% complete response rate at 12 months. Management highlighted that it is easier to administer than JELMYTO and ta...
- Market Penetration Strategy — UroGen is targeting high-decile doctors and large community practices to maximize ZUSDURI's market penetration. The company aims for less than 20% penetration to achieve a $1 billion-plus revenue target.
- UGN-103 Development — UGN-103 is positioned as the next-generation product for ZUSDURI, with a filing expected by Q3 2026. It offers logistical advantages such as longer shelf life and easier preparation.
- Reimbursement and Operational Challenges — The company is addressing reimbursement challenges by providing comprehensive support to doctors' offices, including field reimbursement managers and regional operations managers.
Read the full UroGen Pharma Ltd. transcript (June 10, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About UroGen Pharma Ltd.
UroGen Pharma Ltd. (URGN) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGM and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 46 calls on record spanning January 15, 2020 to November 4, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 46 UroGen Pharma Ltd. earnings call transcripts on record, spanning January 15, 2020 to November 4, 2026. Based on this history, UroGen Pharma Ltd. reports quarterly. The most recent call on file is dated November 4, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- URGN
- Exchange
- NasdaqGM
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 46
- First call
- January 15, 2020
- Most recent
- November 4, 2026
- Reporting cadence
- quarterly